14 results about "Astragaloside II" patented technology

The invention relates to the technical field of biological medicines and ophthalmic medicines, in particular to a herbal exosome composition for eye care and treatment and a preparation method thereof. The composition comprises a synergistic combination of herbal exosomes and mesenchymal stem cell exosomes, and further comprises a nano slow-release carrier system. Wherein the herbal exosome is extracted from a traditional herbal plant liquorice by combining gradient centrifugation with a molecular exclusion chromatography method, and herbal active ingredients, namely astragaloside and quercetin, are loaded in the exosome by adopting an electroporation method, so that the pharmacological activity of the exosome is enhanced. The nano slow-release carrier system is of a two-phase slow-release structure; an inner phase is a phospholipid complex loaded with herbal exosomes and mesenchymal stem cell exosomes, and an outer phase is temperature-sensitive hydrogel; the compound is in a liquid state at room temperature, and is rapidly converted into a gel state after being dropped into the ocular surface, so that the retention time of the medicine on the ocular surface is remarkably prolonged, the bioavailability is improved, and the targeting slow release capability aiming at ocular surface tissues is endowed to the compound.

The invention provides lactobacillus reuteri GY-18 and application thereof in increasing the content of astragaloside, and belongs to the technical field of microorganisms, fermentation and natural product biotransformation. The lactobacillus reuteri GY-18 capable of improving the content of astragaloside in a fermented astragalus membranaceus product is obtained through screening, the lactobacillus reuteri GY-18 is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC M 20252796, and the lactobacillus reuteri GY-18 can be used for improving the content of astragaloside in the fermented astragalus membranaceus product. The lactobacillus reuteri GY-18 can secrete acetylxylan esterase for promoting conversion of astragaloside into astragaloside IV, has efficient specificity on conversion of astragaloside into astragaloside IV, and is high in conversion capacity; according to the method, the content of astragaloside IV is remarkably increased within 24 hours in a semi-solid state fermentation mode, and the method has good practicability.

The invention provides a broad-spectrum combined medicine for treating colorectal cancer. The broad-spectrum combined medicine is prepared from the following components in parts by weight: 100 parts of purified water, 38 to 90 parts of tripterygium wilfordii alkaloid, 38 to 90 parts of tripterygium hypoglaucum alkaloid, 28 to 85 parts of chamaejasmine, 28 to 85 parts of gelsmium elegans alkaloid and 28 to 85 parts of xanthoxylin. The medicine is prepared from the following raw materials in parts by weight: 16 to 80 parts of ganoderan, 16 to 80 parts of pinellia ternate sitosterol, 16 to 80 parts of radix rehmanniae praeparata, 16 to 80 parts of astragaloside, 16 to 80 parts of oldenlandia diffusa alkaloid, 16 to 80 parts of sculellaria barbata alkaloid, 16 to 80 parts of tanshinone, 16 to 80 parts of carthamin, 16 to 80 parts of honeysuckle chlorogenic acid and 16 to 80 parts of pericarpium citri reticulatae flavone. By integrating anti-tumor components with multiple action mechanisms, tripterygium wilfordii alkaloid, tripterygium hypoglaucum alkaloid and the like, tumor cell proliferation can be directly inhibited, and apoptosis can be induced; tanshinone, emodin and the like can inhibit tumor angiogenesis; ganoderma lucidum polysaccharides, astragaloside and the like can activate the immune system of the body, enhance the activity of T cells and NK cells, and form double strikes of direct killing and immune surveillance.

The invention provides a pharmaceutical composition for preventing and / or treating lung cancer. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-2 parts of astragaloside, 1-2 parts of codonopsis pilosula polysaccharide and 0.5-1 part of pericarpium citri reticulatae flavone. The invention also provides a preparation method and application of the pharmaceutical composition. High-purity effective parts such as astragaloside, codonopsis pilosula polysaccharide and pericarpium citri reticulatae flavone are prepared, the specific compatibility proportion of the astragaloside, the codonopsis pilosula polysaccharide and the pericarpium citri reticulatae flavone is optimized, and it is found through in-vivo and in-vitro activity research that after compatibility of the astragaloside, the codonopsis pilosula polysaccharide and the pericarpium citri reticulatae flavone, the obvious lung cancer inhibiting effect is achieved, and after compatibility, the obvious synergistic interaction effect can be achieved.

The application belongs to the technical field of biological medicine, and provides application of astragaloside IV in preparation of a medicine for treating advanced ovarian cancer. The application analyzes and studies a targeting effect of AS-IV on CD276, determines a molecular mode of covalent combination of AS-IV and CD276, identifies a molecular mechanism of combination of AS-IV and CD276 through an E3 ubiquitin ligase and activation of an mTORC1 pathway of NK cells, and determines application potential of AS-IV in enhancement of NK cell anti-tumor immunity in preparation of an OC immunotherapy medicine.

This invention relates to the fields of biomedicine and ophthalmic drug technology, specifically to an herbal exosome composition for eye care and treatment and its preparation method. The composition comprises a synergistic combination of herbal exosomes and mesenchymal stem cell exosomes, and also includes a nano-sustained-release carrier system. The herbal exosomes are extracted from the traditional herb licorice using gradient centrifugation combined with size exclusion chromatography, and the active herbal components astragaloside and quercetin are loaded onto the exosomes using electroporation to enhance their pharmacological activity. The nano-sustained-release carrier system has a biphasic sustained-release structure: the inner phase is a phospholipid complex carrying herbal exosomes and mesenchymal stem cell exosomes, and the outer phase is a thermosensitive hydrogel; it is liquid at room temperature, but rapidly transforms into a gel state after being instilled onto the ocular surface, significantly prolonging the drug's residence time on the ocular surface, improving bioavailability, and endowing it with targeted sustained-release capability against ocular surface tissues.

The invention discloses a composition which is used for preventing and / or treating cholestasis hepatic fibrosis and contains astragaloside I and calycosin-7-glucoside. The mass concentration ratio of the astragaloside I to the calycosin-7-glucoside is (1-5): (40-60), or (20-40): (0.5-2), or (40-60): (0.5-15). The composition disclosed by the invention has an excellent effect of resisting cholestasis hepatic fibrosis, and can be used for improving serum liver functions and bile duct reactions and reducing collagen deposition and inflammatory reactions.

The invention relates to a B cell inhibitor and application thereof in preparation of drugs for treating xerophthalmia. The present invention relates to a B cell activity inhibitor selected from the group consisting of formononetin; formononin; astragaloside IV; total flavonoids of an astragalus extract; the components are astragaloside IV and formononetin; astragaloside IV and formononin; the composition is prepared from astragaloside I, astragaloside IV, formononin and formononetin. Compared with the side effect of cyclosporine in the prior art (which is within the renal toxicity of 1 / 3 of a patient who takes the medicine), the astragalus extract general flavone has the effect of inhibiting the activity of B cells so as to inhibit humoral immunity. On the basis of the research on the disease mechanism of pSS, the specific astragalus membranaceus extract general flavone which can be used as a medicine for administration and a medicine for instillation is developed.

The invention relates to the technical field of breeding, in particular to a senescence delaying type Chinese herbal medicine additive for laying hens in the later egg laying period. The matrix dispersed nano-micelle included traditional Chinese medicine compound extract is prepared from the following raw materials in parts by weight: extracts of eight traditional Chinese medicine raw materials and sodium cholate-chitosan quaternary ammonium salt ionic liquid, and the eight traditional Chinese medicine raw materials are as follows: motherwort, glossy privet fruit, astragalus membranaceus, angelica sinensis, dandelion, fructus lycii, poria cocos and hawthorn. According to the invention, an adjusting network formed by compatibility of the traditional Chinese medicine components realizes accurate release and synergistic effect in the body of the laying hen through efficient delivery of the ionic liquid nano-micelles: leonurine and astragaloside act together, so that the ovarian function decline speed is slowed down, and the laying rate is maintained at 82% or above; polysaccharide and flavonoid components synergistically enhance the oxidation resistance, the serum SOD activity is improved to 240 U / mL or above, the MDA content is reduced to 5.2 nmol / mL or below, and the aging process of an organism is delayed.

The invention belongs to the field of traditional Chinese medicine preparations, and discloses radix astragali and rhizoma atractylodis macrocephalae healing-promoting oral granules for regulating a chronic wound microenvironment, a preparation process of the granules and application of the granules in chronic wound treatment. The radix astragali and rhizoma atractylodis macrocephalae healing promoting oral granules are prepared from 25-35 parts of raw radix astragali, 10-20 parts of radix pseudostellariae, 10-20 parts of fried rhizoma atractylodis macrocephalae, 25-35 parts of radix salviae miltiorrhizae, 10-20 parts of fructus lycii and 10-20 parts of fructus corni through gradient ethanol extraction and astragaloside enrichment processes. According to the granules, systematic regulation of wound surface microenvironment steady state is realized in an oral dosage form for the first time, and triple pathological links of high glucose-infection-ischemia of chronic wound surfaces are synchronously improved through a synergistic effect of a dogwood fruit pulp blood glucose reducing component and a high-proportion astragalus membranaceus / salvia miltiorrhiza healing promoting component; clinical tests show that when the oral granules are singly used for treating the deep chronic refractory ulcer, the healing time is shortened by 32% compared with that of red ointment, and the healing rate is increased to 76.3%.

The present application relates to the technical field of cell engineering, and particularly relates to a culture medium for producing biological antibodies and a fermentation method thereof.The culture medium comprises a basic culture medium and a fermentation culture medium; the basic culture medium is based on a commercial culture medium and comprises the following components: fumaric acid, ferric ammonium citrate, astragaloside and baicalein; the fermentation culture medium is based on a commercial culture medium and comprises the following components: L-citrulline, L-ornithine, L-theanine, L-homoarginine, L-hydroxyproline, L-allo-threonine, mannose, isorhamnetin and ginkgolin.The culture medium combination can effectively improve the expression level of target antibodies, supports cells to maintain long-term activity in a high-density state; meanwhile, the charge variant distribution of the obtained antibodies is more uniform, and the product purity and consistency are significantly improved.

The invention provides a method for determining the content of multiple components in an Aidi preparation, and belongs to the technical field of medicines. The Aidi preparation is prepared from traditional Chinese medicinal materials including ginseng, cantharides, astragalus membranaceus and acanthopanax. The content determination method comprises the following steps: simultaneously determining cantharidin, ginsenoside Rg1, ginsenoside Re, ginsenoside Rb1, ginsenoside Rc, ginsenoside Rd, isofraxidin, syringin, formononetin, astragaloside, chlorogenic acid, eleutheroside E, calycosin-7-glucoside, astragaloside II, neochlorogenic acid, cryptochlorogenic acid and eleutheroside E1 in the Aidi preparation by adopting liquid chromatography-mass spectrometry; the composition is prepared from effective components such as ginsenoside F3, ginsenoside Rg2, azelaic acid and the like. Compared with the prior art, the method has the advantages that the contents of the 20 effective components in the Aidi preparation are simultaneously measured under the same chromatographic condition through liquid chromatography-mass spectrometry, the method is convenient and rapid, the requirement for product quality detection is greatly improved, the method is more suitable for quality control of drugs in the future, and the drug quality and the clinical drug effect are guaranteed.

The invention discloses a composition used for preventing and / or treating cholestatic hepatic fibrosis and containing astragaloside I and calycosin. The mass concentration ratio of the astragaloside I to the calycosin is (1-5): (40-60), or (1-10): (1-5), or (8-20): (40-60), or (20-40): (0.5-2), or (40-60): (40-60). The composition disclosed by the invention has an excellent effect of resisting cholestasis hepatic fibrosis, and can improve serum liver function, fibrosis degree and bile duct reaction and reduce collagen deposition and inflammatory response.